Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Veracyte is poised for long-term growth as they continue to expand their presence in the cancer diagnostics market with their innovative technology and partnerships. Despite facing challenges in scaling efficiently, their strong financial profile and evidence-based validation for their tests make them a leader in this industry. With a focus on acquisitions and expanding their tests, Veracyte is well-positioned to increase market share and revenue in the coming years.

Bears say

Veracyte is a genomic diagnostics company with a negative outlook due to its heavy reliance on just two flagship assets, as well as potential reimbursement risks, product concentration, and competition. While both core franchises are still accelerating, there are concerns about the company's ability to reach its long-term penetration targets. Additionally, the company's pipeline is viewed as underappreciated and represents a risk to the company's growth. Despite strong revenue growth and the potential for future growth, the risk factors and reliance on a few key products warrant a cautious outlook.

Veracyte (VCYT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 9 analysts, Veracyte (VCYT) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.